NCT04491370: An ongoing trial by New York Medical College
This trial is ongoing. It must report results 4 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04491370 |
|---|---|
| Title | Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 1, 2021 |
| Completion date | Aug. 15, 2024 |
| Required reporting date | Aug. 15, 2025, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |